ArticleViruses2022
Strong SARS-CoV-2 N-Specific CD8
Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Extracellular vesicles as vaccine platforms: emerging opportunities for malaria.Frontiers in immunology · 2026Review
- Extracellular vesicles as new-age vaccine carriers: a focused account on viral diseases.Frontiers in immunology · 2026Review
- Dual Role of Extracellular Vesicles as Orchestrators of Emerging and Reemerging Virus Infections.Cell biochemistry and biophysics · 2025Review
- Extracellular vesicle-based anti-HOXB7 CD8Cancer gene therapy · 2024Article
- B and T Cell Bi-Cistronic Multiepitopic Vaccine Induces Broad Immunogenicity and Provides Protection Against SARS-CoV-2.Vaccines · 2024Article
- Review
- SARS-CoV-2-Specific CD8Vaccines · 2023Article
- Article
- Antiviral effect of SARS-CoV-2 N-specific CD8NPJ vaccines · 2023Article
- Extracellular vesicles in COVID-19 prognosis, treatment, and vaccination: an update.Applied microbiology and biotechnology · 2023Review
- Plant-Derived Extracellular Vesicles as a Delivery Platform for RNA-Based Vaccine: Feasibility Study of an Oral and Intranasal SARS-CoV-2 Vaccine.Pharmaceutics · 2023Article
- T cell immune memory after covid-19 and vaccination.BMJ medicine · 2023Review
- Different configurations of SARS-CoV-2 spike protein delivered by integrase-defective lentiviral vectors induce persistent functional immune responses, characterized by distinct immunogenicity profiles.Frontiers in immunology · 2023Article
- Meet changes with constancy: Defence, antagonism, recovery, and immunity roles of extracellular vesicles in confronting SARS-CoV-2.Journal of extracellular vesicles · 2022Review
- Activation of Anti-SARS-CoV-2 Human CTLs by Extracellular Vesicles Engineered with the N Viral Protein.Vaccines · 2022Article
- COVID-19 Vaccines: Current and Future Perspectives.Vaccines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
SARS-CoV-2-specific CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.